GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
Live video webcast on Wednesday, July 17th at 12:00 PM ET
将在美国东部时间7月17日下午12:00进行实时视频网络直播
LA JOLLA, CA, July 15, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024 at 12:00 PM ET.
2024年7月15日，加州拉霍亚 — GRI Bio, Inc. (纳斯达克: GRI) ("GRI生物", "我们", "我们的"或"公司")，一家生物技术公司正在推动一系列自然杀伤T（NKT）细胞调节剂的创新管道，用于治疗炎症、纤维化和自身免疫性疾病，今天宣布将参加。于2024年7月17日下午12:00 Pm Et连线。
As part of the event, Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
作为该活动的一部分，GRI Bio的首席执行官Marc Hertz博士将提供公司概述和业务展望。除了经过调整的讨论外，投资者和有兴趣的各方还将有机会在活动期间实时提交问题。该公司将在允许的时间内回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
机器人演示的网络直播视频将在公司网站（aimimmuno.com）的“活动”页面上提供。演示的网络直播视频将在现场演示后两小时提供，并可访问90天。有关AIM Immunotech股份有限公司的信息，请访问aimimmuno.com并与公司联系。公司主页投资者，详见公司网站（gribio.com)。演讲的网络直播视频将在现场演示后两小时提供，并可访问90天。
About GRI Bio, Inc.
关于GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家临床阶段的生物制药公司，专注于从根本上改变炎症，纤维化和自身免疫性疾病的治疗方式。 GRI Bio的治疗疗法旨在针对NKT细胞的活性，这些细胞是炎症级联中早期的关键调节因子，以阻断疾病进程并恢复免疫系统的稳态。 NKT细胞是一种类似本能型t细胞的细胞，它们具有Nk细胞和t细胞的特性，是本能型和适应性免疫反应之间的功能链接。类型1不变（iNKT）细胞在炎症和纤维化症状中起着传播损伤，炎症反应和纤维化的关键作用。 GRI Bio的领先项目GRI-0621是iNKt细胞活性的抑制剂，正在开发中作为治疗特发性肺纤维化的新型口服疗法，该疾病极具需求。 该公司还在开发一系列用于系统性红斑狼疮治疗的新型第二代NKt激动剂。 此外，凭借超过500种专有化合物的库，GRI Bio具有推动日益增长的管道的能力。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
投资者联系人：
JTC Team，LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
